The immunohistochemistry laboratory looking at molecules and preparing for tomorrow

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 11, 2010, Pages 1659-1665

  Teruya Feldstein, Julie ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY; MOLECULAR PATHOLOGY; PROTEOMICS;

GENOMICS; HUMANS; IMMUNOHISTOCHEMISTRY; LABORATORIES; PATHOLOGY, MOLECULAR; PROTEOMICS;

EID: 78249251787     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Coleman R. The impact of histochemistry-a historical perspective. Acta Histochem. 2000;102(1):5-14.
2. Moreau A, Le Neel T, Joubert M, Truchaud A, Laboisse C. Approach to automation in immunohistochemistry. Clin Chim Acta. 1998;278(2):177-184.
3. True LD. Quality control in molecular immunohistochemistry. Histochem Cell Biol. 2008;130(3):473-480.
4. Taylor CR, Levenson RM. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006;49(4):411-424.
5. Zhang D, Denley RC, Filippa DA, Teruya-Feldstein J. ALK-positive diffuse large B-cell lymphoma with the t(2;17)(p23;q23). Appl Immunohistochem Mol Morphol. 2009;17(2):172-177.
6. Ladanyi M. Aberrant ALK tyrosine kinase signaling: different cellular lineages, common oncogenic mechanisms. Am J Pathol. 2000;157(2):341-345.
7. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001;20(40):5623-5637.
8. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008;455(7215):971-974.
9. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008; 455(7215):967-970.
10. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455(7215):930- 935.
11. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215):975-978.
12. Chan JK, Lamant L, Algar E, et al. ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood. 2008;112(7): 2965-2968.
13. Perez-Pinera P, Chang Y, Astudillo A, Mortimer J, Deuel TF. Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer. Biochem Biophys Res Commun. 2007;358(2):399-403.
14. Li R, Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev. 2008;28(3):372-412.
15. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11-23.
16. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153): 561-566.
17. Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009;9(3):331-356.
18. Hsi ED, Yegappan S. Lymphoma immunophenotyping: a new era in paraffin-section immunohistochemistry. Adv Anat Pathol. 2001;8(4):218-239.
19. Teruya-Feldstein J. Getting the diagnosis right in NHL: role of immunohistochemistry and molecular diagnostic testing. J Natl Compr Canc Netw. 2008; 6(4):422-427.
20. Wick MR. Immunohistochemical approaches to the diagnosis of undifferentiated malignant tumors. Ann Diagn Pathol. 2008;12(1):72-84.
21. Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol. 2009;36(1):8-37.
22. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
23. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494-5502.
24. Hsi ED. The search for meaningful prognostic markers in diffuse large Bcell lymphoma. Am J Clin Pathol. 2001;115(4):481-483.
25. de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25(7):805-812.
26. de Jong D, Xie W, Rosenwald A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol. 2009;62(2):128-138.
27. Hagenbeek A, Gascoyne RD, Dreyling M, et al. Biomarkers and prognosis in malignant lymphomas. Clin Lymphoma Myeloma. 2009;9(2):160-166.
28. Hsi ED. The role of biomarkers in the management of patients with lymphoma: promise versus reality. Clin Lymphoma Myeloma. 2009;9(2):121-123.
29. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21(suppl 2):S8-S15.
30. Hsi ED. A practical approach for evaluating new antibodies in the clinical immunohistochemistry laboratory. Arch Pathol Lab Med. 2001;125(2):289-294.
31. Sullivan CA, Chung GG. Biomarker validation: in situ analysis of protein expression using semiquantitative immunohistochemistry-based techniques. Clin Colorectal Cancer. 2008;7(3):172-177.
32. Packeisen J, Buerger H, Krech R, Boecker W. Tissue microarrays: a new approach for quality control in immunohistochemistry. J Clin Pathol. 2002;55(8): 613-615.
33. Hsu FD, Nielsen TO, Alkushi A, et al. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol. 2002; 15(12):1374-1380.
34. Giltnane JM, Rimm DL. Technology insight: identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol. 2004;1(2):104-111.
35. Warford A, Howat W, McCafferty J. Expression profiling by highthroughput immunohistochemistry. J Immunol Methods. 2004;290(1-2):81-92.
36. Eguiluz C, Viguera E, Millan L, Perez J. Multitissue array review: a chronological description of tissue array techniques, applications and procedures. Pathol Res Pract. 2006;202(8):561-568.
37. Warford A, Flack G, Conquer JS, Zola H, McCafferty J. Assessing the potential of immunohistochemistry for systematic gene expression profiling. J Immunol Methods. 2007;318(1-2):125-137.
38. Powell WC, Hicks DG, Prescott N, et al. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol. 2007;15(1):94-102.
39. Paterson JC, Ballabio E, Mattsson G, et al. Labeling of multiple cell markers and mRNA using automated apparatus. Appl Immunohistochem Mol Morphol. 2008;16(4):371-381.
40. Powell RD, Pettay JD, Powell WC, et al. Metallographic in situ hybridization. Hum Pathol. 2007;38(8):1145-1159.
41. Gown AM, Goldstein LC, Barry TS, et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol. 2008;21(10):1271-1277.
42. Downing JR. Targeted therapy in leukemia. Mod Pathol. 2008; 21(suppl 2):S2-S7.
43. Antonescu CR. Targeted therapies in gastrointestinal stromal tumors. Semin Diagn Pathol. 2008;25(4):295-303.
44. Antonescu CR. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol. 2008;21(suppl 2):S31-S36.
45. Ladanyi M. Targeted therapy of cancer: new roles for pathologists. Mod Pathol. 2008;21(suppl 2):S1.
46. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008;21(suppl 2):S16-S22.
47. Hamilton SR. Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol. 2008;21(suppl 2):S23-S30.
48. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008;21(suppl 2):S37-S43.
49. Rubin MA. Targeted therapy of cancer: new roles for pathologists- prostate cancer. Mod Pathol. 2008;21(suppl 2):S44-S55.
50. Yang Y, Pospisil P, Iyer LK, Adelstein SJ, Kassis AI. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer. PLoS ONE. 2008;3(11):e3661. doi:10.1371/journal.pone. 0003661.
51. Jain KK. Oncoproteomics: state-of-the-art. Technol Cancer Res Treat.2002;1(4):219-220.
52. Jain KK. Recent advances in oncoproteomics. Curr Opin Mol Ther. 2002; 4(3):203-209.
53. Jain KK. Role of oncoproteomics in the personalized management of cancer. Expert Rev Proteomics. 2004;1(1):49-55.
54. Jain KK. Recent advances in clinical oncoproteomics. J BUON. 2007; 12(suppl 1):S31-S38.
55. Sikder MA, Friedberg JW. Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Curr Oncol Rep. 2008;10(5):420-426.
56. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43.
57. Dorfman DM, Bui MM, Tubbs RR, et al. The CD117 immunohistochemistry tissue microarray survey for quality assurance and interlaboratory comparison: a College of American Pathologists Cell Markers Committee Study. Arch Pathol Lab Med. 2006;130(6):779-782.
58. Mitsiades CS, Mitsiades N. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. Expert Rev Anticancer Ther. 2005;5(3):487-499.
59. Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov. 2009;4(1):54-72.
60. Qi H, Xiao L, Lingyun W, et al. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis. Ann Hematol. 2006;85(2):95-101.